Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting [Yahoo! Finance]
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes [Yahoo! Finance]
Moderna (MRNA) had its price target raised by Barclays PLC from $25.00 to $48.00. They now have an "equal weight" rating on the stock.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)? [Yahoo! Finance]
Looking for Small-Cap Value? Consider These 2 ETFs [Yahoo! Finance]